Loading
Latest filing published 27 Nov 2023 for Elite Pharmaceuticals INC, €18k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Davis S. Caskey discloses dealings in Elite Pharmaceuticals Inc to SEC (Form 4). Between 23 February 2017 and 22 November 2023, the trades on record add up to 6 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 27 November 2023 with a share grant (€18k) in Elite Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations